Back to Search Start Over

Optimizing emetic control in children receiving antineoplastic therapy: beyond the guidelines.

Authors :
Dupuis LL
Nathan PC
Source :
Paediatric drugs [Paediatr Drugs] 2010; Vol. 12 (1), pp. 51-61.
Publication Year :
2010

Abstract

Existing guidelines for the prevention of antineoplastic chemotherapy-induced nausea and vomiting (CINV) in children are constrained by the lack of robust evidence. Current guidelines recommend the use of a serotonin 5-HT(3) receptor antagonist plus a corticosteroid to prevent acute CINV. Consequently, antiemetic agents that are recommended for use in adult cancer patients do not appear in the current pediatric guidelines. In addition, there is no information to guide the selection of alternative antiemetic agents for children who either cannot receive the recommended agents or who do not respond adequately to the treatment. Possible barriers to adherence to the pediatric antiemetic selection guidelines that are currently available are discussed, and published pediatric experience with antiemetic agents recommended in the current adult antiemetic selection guidelines (dolasetron, tropisetron, palonosetron, aprepitant) is summarized in this review. The use of novel and emerging antiemetic therapeutic interventions {metopimazine, diphenhydramine (Benadryl)-lorazepam (Avitan)-dexamethasone (Decadron) [BAD], nabilone, acupuncture, midazolam, olanzapine, mirtazapine, gabapentin, droperidol} in children are explored.

Details

Language :
English
ISSN :
1179-2019
Volume :
12
Issue :
1
Database :
MEDLINE
Journal :
Paediatric drugs
Publication Type :
Academic Journal
Accession number :
20034341
Full Text :
https://doi.org/10.2165/11316190-000000000-00000